Dermapharm Holding SE (CHIX:DMPD) Additional Paid-In Capital: €92 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DMPD Dermapharm Holding SE CHIX:DMPD
80 GF Score
Price €46.18
GF Value €44.50
! 5 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Additional Paid-In Capital?

Dermapharm Holding SE CHIX:DMPD 80 Additional Paid-In Capital is €92 Mil as of Jun. 2026. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €44.50. The stock has 5 warning signs investors should review.


Dermapharm Holding SE's quarterly additional paid-in capital stayed the same from Dec. 2025 (€101 Mil) to Mar. 2026 (€101 Mil) and stayed the same from Mar. 2026 (€101 Mil) to Jun. 2026 (€92 Mil).

Dermapharm Holding SE's annual additional paid-in capital stayed the same from Dec. 2023 (€101 Mil) to Dec. 2024 (€101 Mil) and stayed the same from Dec. 2024 (€101 Mil) to Dec. 2025 (€101 Mil).

Dermapharm Holding SE Additional Paid-In Capital Related Terms

Dermapharm Holding SE Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Additional Paid-In Capital Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.79 100.79 100.79 100.79 100.79

Dermapharm Holding SE Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.79 100.79 100.79 100.79 92.47
CHIX:DMPD
80GF Score
Dermapharm Holding SE CHIX:DMPD
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of €92 Mil mean?
Dermapharm Holding SE (CHIX:DMPD) has a Additional Paid-In Capital of €92 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Dermapharm Holding SE and its competitors.
Is Dermapharm Holding SE's Additional Paid-In Capital too high?
Dermapharm Holding SE's current Additional Paid-In Capital is €92 Mil. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Additional Paid-In Capital compare to ZTS and UTHR?
Dermapharm Holding SE's Additional Paid-In Capital of €92 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Drug Manufacturers company?
A good Additional Paid-In Capital depends on the Drug Manufacturers industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Additional Paid-In Capital is €92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Additional Paid-In Capital of €92 Mil. The stock's GF Value™ is €44.50, compared to a current price of €46.18 — trading 3.8% above its estimated fair value. The current Additional Paid-In Capital is €92 Mil. Dermapharm Holding SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Additional Paid-In Capital is €92 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.18 is trading 3.8% above its estimated GF Value™ of €44.50.

Key valuation signals for CHIX:DMPD:

  • Additional Paid-In Capital: €92 Mil
  • GF Value™: €44.50 vs. price of €46.18 (3.8% above fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dermapharm Holding SE Business Description

Other Exchanges DMPHF:USA0A5J:UKDMP:Germany
Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score

Get the complete analysis for CHIX:DMPD

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.18
Price
€44.50
GF Value